glp-1 receptor agonists in idiopathic intracranial hypertension Novel use of agonist therapy for pediatric hypertension: a case report Use of glucagon-like peptide-1 receptor

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis

13 The median expected protection we determined for GLP-1 receptor agonistswhich exceeds 18 yearsis the highest yet reported for drug-device combinations

The present study aims to investigate comparative dementia risk with initiators of GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors in people with type 2 diabetes aged 60 years, using real-world observational data from primary care practice records in the UK

Therefore, in the context of the widespread global utilization of GLP-1RAs, it is imperative to investigate whether a potential relationship exists between GLP-1RAs and SSIBs, which is of paramount importance for public and clinical medication safety

By promoting oxygen consumption in brown adipose tissue (BAT), glucagon increases metabolic rate

When the body loses weight rapidly, whether through caloric restriction, surgical intervention, or pharmacological appetite suppression, it does not selectively shed fat